|
|
|
|
|
12.02.26 - 07:00
|
Camurus′ Full Year Report 2025 (Cision)
|
|
|
“Fourth quarter performance paves the way for a productive 2026”
Fourth quarter and full year summary
October - December
· Total revenues decreased 16% (3% at CER[1]) to SEK 464 (553) million, impacted by a one-time repurchase of inventory of 93 MSEK due to a change of the UK distribution model at the end of the period
· Product sales decreased 27% (17% at CER[1]) to SEK 342 (469) million
· Royalties increased 47% (82% at CER[1]) to SEK 122 (83) million
· Profit before tax decreased 32% (0% at CER[1]) to SEK 127 (186) million
· The cash position at the end of the...
|
|
|
22.01.26 - 09:54
|
AKTIONÄR-Tipp Camurus: "Top-Pick" – mit Eli Lilly in neue Dimensionen (Der Aktionaer)
|
|
|
Die Aktie des schwedischen Biotech-Unternehmens Camurus hat sich in den zurückliegenden Monaten sehr volatil entwickelt. Die Analysten von ABG Sundal Collier (ABGSC) trauen dem Papier allerdings neue Rekorde zu. DER AKTIONÄR erklärt, was jetzt für einen Kauf der Anteile der Skandinavier spricht, die unter anderem mit dem Pharma-Riesen Eli Lilly zusammenarbeiten....
|
|
|
|
|
30.12.25 - 07:00
|
Change in number of shares and votes in Camurus (Cision)
|
|
|
Lund, Sweden — 30 December 2025 — During December 2025, 7,350 employee stock options in Camurus' employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares.
As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 7,350.
Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,872,834 corresponding to 59,872,834 votes. As of 30 December 2025, the total number of shares in Camurus amounts to 59,880,184 corresponding to...
|
|
|
16.12.25 - 11:57
|
Gubra und Camurus: 2 AKTIONÄR-Tipps, ein Ziel – die Hintergründe! (Der Aktionaer)
|
|
|
Die beiden skandinavischen Biotech-Gesellschaften Camurus und Gubra bündeln ihr Know-how. Eine aufgesetzte exklusive Kooperations- und Lizenzvereinbarung dient dem Ziel die Entwicklung einer langwirksamen Therapieoption für die Behandlung von Hypoparathyreoidismus, einer Unterfunktion der Nebenschilddrüsen....
|
|
|
16.12.25 - 11:30
|
Camurus and Gubra enter into a collaboration and license agreement to develop a long-acting treatment for hypoparathyroidism (Cision)
|
|
|
Lund, Sweden and Hørsholm, Denmark — 16 December 2025 — Camurus (NASDAQ STO: CAMX) and Gubra, a company specialized in peptide-based drug discovery, today announced that the companies have entered into an exclusive collaboration and license agreement aimed at creating a long-acting therapeutic option for the treatment of hypoparathyroidism.
This research and development collaboration will combine Gubra's parathyroid hormone (PTH) analogue, developed using the company's proprietary streaMLine peptide discovery platform, with Camurus' FluidCrystal[®] drug delivery technology to enable...
|
|
|
28.11.25 - 07:00
|
Change in number of shares and votes in Camurus (Cision)
|
|
|
Lund, Sweden — 28 November 2025 — During November 2025, 24,200 employee stock options in Camurus' employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of registered shares.
As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 24,200.
Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,848,634 corresponding to 59,848,634 votes. As of 28 November 2025, the total number of shares in Camurus amounts to 59,872,834 corresponding to...
|
|
|
13.11.25 - 07:00
|
Camurus′ Nomination Committee appointed for the Annual General Meeting 2026 (Cision)
|
|
|
Lund, Sweden — 13 November 2025 — Camurus today announced that the Nomination Committee for the Annual General Meeting (AGM), 2026 consists of the following persons, who together represent about 40 percent of the total number of shares and votes in Camurus based on the last known shareholder information:
· Per Sandberg, appointed by Sandberg Development AB,
· Arne Lööw, appointed by Fjärde AP-fonden,
· Oscar Bergman, appointed by Swedbank Robur Fonder, and
· Per Olof Wallström, Chairman of the Board of Camurus
The Nomination Committee's proposals will be presented in the...
|
|
|
12.11.25 - 10:02
|
Camurus to present at Jefferies London Healthcare Conference (Cision)
|
|
|
Lund, Sweden — 12 November 2025 — Camurus (NASDAQ STO: CAMX) will attend the Jefferies Global Healthcare Conference in London 17–20 November. President and CEO Fredrik Tiberg will present on 18 November at 9.30 am CET, giving an update on the company's recent developments.
A webcast of the presentation can be accessed via:
https://wsw.com/webcast/jeff332/register.aspx?conf=jeff332&page=camx&url=https://wsw.com/webcast/jeff332/camx/1839403
For more information
Fredrik Joabsson, Chief Business Development Officer
Tel. +46 (0)70 776 17 37
ir@camurus.com (mir@camurus.com)
About...
|
|
|
10.11.25 - 10:01
|
AKTIONÄR-Tipp Camurus: Gamechanger im Adipositas-Markt? Kurssprung! (Der Aktionaer)
|
|
|
Der Adipositas-Markt zählt innerhalb der Biopharma-Branche weiterhin zu den heißesten Bereichen – nicht zuletzt durch den Bieterkampf zwischen Pfizer und Novo Nordisk um Metsera. Unlängst verschiebt sich der Fokus bei der Entwicklung auf weitere Parameter neben der absoluten Gewichtsreduktion in einem bestimmten Zeitraum....
|
|
|
|
|
|
|
|
|
06.11.25 - 07:06
|
Camurus′ Interim Report Third Quarter 2025 (Cision)
|
|
|
“High profitability and launch preparations for Oczyesa[®]”
Summary third quarter 2025
July - September
· Total revenues grew 18% (25% at CER[1]) to SEK 567 (480) million
· Sales of Buvidal[®] increased 8% (15% at CER[1]) to SEK 455 (421) million
· Brixadi[®] royalties increased 91% (100% at CER[1]) to SEK 111 (58) million
· Profit before tax increased 48% to SEK 245 (165) million
· The cash position at the end of the quarter was SEK 3.5 (2.8) billion
· Oczyesa[®] (CAM2029) approved in the UK for the treatment of acromegaly
· FDA and the European Commission...
|
|
|
03.11.25 - 08:06
|
Camurus launches long-acting Oczyesa® for the treatment of acromegaly (Cision)
|
|
|
· Oczyesa now available to patients with acromegaly in Germany
· First once-monthly, subcutaneous octreotide treatment
· Developed for self-administration and effective disease control
Lund, Sweden — 3 November 2025 — Camurus (NASDAQ STO: CAMX) today announced the introduction of Oczyesa[ ]in Germany, as the first country in the EU. Oczyesa[®],[ ]octreotide subcutaneous depot, is approved for the maintenance treatment in adults with acromegaly who have responded to and tolerated treatment with somatostatin analogs.[1 ]
”We are pleased to announce that Oczyesa is now available to...
|
|
|
14.10.25 - 13:01
|
AcuCort strengthens its management team with the appointment of Anna Chérouvrier Hansson as Business Development Director (Cision)
|
|
|
AcuCort has appointed Anna Chérouvrier Hansson as its Business Development Director. The appointment is part of AcuCort's continued commercial development and focus on strengthening strategic partnerships to support the launch of Zeqmelit® in additional markets.
Anna Chérouvrier Hansson brings more than 15 years of experience in business development, sales and marketing within the life science sector. She has held senior positions in both listed companies and fast-growing SMEs, including SenzaGen and Camurus.
At SenzaGen, she played a key role in building and driving the company's...
|
|
|
30.09.25 - 07:06
|
Change in number of shares and votes in Camurus (Cision)
|
|
|
Lund, Sweden — 30 September 2025 — During September 2025, 188,050 employee stock options in Camurus' employee stock options program ESOP 2022/2026 have been exercised for subscription of the corresponding number of shares.
As a result of the exercises made under ESOP 2022/2026, the number of shares and votes has increased by 188,050.
Prior to the exercises of employee stock options, the total number of shares in Camurus amounted to 59,660,584 corresponding to 59,660,584 votes. As of 30 September 2025, the total number of shares in Camurus amounts to 59,848,634 corresponding to 59,...
|
|
|
15.09.25 - 15:30
|
Exercise in Camurus′ employee stock options program 2022/2026 (Cision)
|
|
|
Lund, Sweden — 15 September 2025 — During September 2025, a total of 177,950 options in Camurus AB's employee stock options program (ESOP) 2022/2026 have been exercised for the corresponding number of shares, at an exercise price of SEK 237.40 per share. Through the exercise of the employee stock options, Camurus receives a total of SEK 42,245,330.
A number of employees and senior executives of Camurus have participated in two forms of cashless exercise, where shares have been sold either in such number that was required to finance the subscription of new shares and taxes related to the...
|
|
|
29.08.25 - 08:03
|
AKTIONÄR-Tipp Camurus: Nächste Zulassung – Bullen am Drücker (Der Aktionaer)
|
|
|
Die schwedische Biotech-Gesellschaft Camurus kann die nächste Marktzulassung verbuchen. Betroffene mit der endokrinologischen Erkrankung Akromegalie in Großbritannien können fortan Oczyesa als Erhaltungstherapie verschrieben bekommen. Indes befindet sich die Aktie von Camurus in bestechender Form und das Allzeithoch in Schlagdistanz....
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
